Tech firm Clario is boosting its electronic clinical outcome assessment (eCOA) offerings by acquiring the neuroscience-focused eCOA business of WCG.
WCG's eCOA services provide specialized expertise in neurology, psychiatry, neuropathic pain and rare diseases, according to a March 10 release.
"WCG's eCOA business has a well-earned reputation for industry-leading expertise in neuroscience," Clario CEO Chris Fikry, M.D., said in the release. "Adding their scientific and operational capabilities to expand our neuroscience capabilities in imaging and digital physiology aligns with Clario's vision to transform lives by unlocking actionable evidence."
The WCG move bolsters Clario’s eCOA services, which already include a digital multimedia platform built on the firm’s 25 years of experience in the field, according to Clario.
Selling its eCOA business will enable WCG to focus on “connecting sponsors and CROs with sites to accelerate trials through trial design, study review, site activation, and participant recruitment and retention," WCG CEO Sam Srivastava said in the release.
Clario made another big M&A move about one year ago when it purchased AI software developer ArtiQ. That buy came six months after another acquisition, that of Inofab Health, a manufacturer of ultrasonic sensor spirometer devices.